Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Lexicon Pharmaceuticals (NASDAQ: LXRX) announced its upcoming participation in the 2025 Jefferies Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for Thursday, June 5 at 12:50 p.m. ET in New York City. Investors and interested parties can access both the live presentation and its replay through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX) ha annunciato la sua prossima partecipazione alla 2025 Jefferies Global Healthcare Conference. Il management dell'azienda parteciperà a una conversazione informale programmata per giovedì 5 giugno alle 12:50 ET a New York City. Investitori e interessati potranno seguire la presentazione in diretta e la sua registrazione nella sezione Eventi del sito web per gli investitori di Lexicon all'indirizzo https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX) anunció su próxima participación en la Conferencia Global de Salud Jefferies 2025. La dirección de la empresa participará en una charla informal programada para el jueves 5 de junio a las 12:50 p.m. ET en la ciudad de Nueva York. Los inversores y partes interesadas podrán acceder tanto a la presentación en vivo como a su repetición a través de la sección Eventos del sitio web de relaciones con inversores de Lexicon en https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX)는 2025 Jefferies 글로벌 헬스케어 컨퍼런스에 참여할 예정임을 발표했습니다. 회사 경영진은 6월 5일 목요일 오후 12시 50분(동부시간) 뉴욕시에서 열리는 파이어사이드 채팅에 참여할 예정입니다. 투자자 및 관심 있는 분들은 Lexicon 투자자 관계 웹사이트의 이벤트 섹션 https://investors.lexpharma.com/에서 라이브 발표와 재방송을 모두 시청할 수 있습니다.
Lexicon Pharmaceuticals (NASDAQ : LXRX) a annoncé sa prochaine participation à la Jefferies Global Healthcare Conference 2025. La direction de l'entreprise participera à une discussion informelle prévue le jeudi 5 juin à 12h50 ET à New York. Les investisseurs et parties intéressées pourront accéder à la présentation en direct ainsi qu'à sa rediffusion via la section Événements du site web des relations investisseurs de Lexicon à l'adresse https://investors.lexpharma.com/.
Lexicon Pharmaceuticals (NASDAQ: LXRX) hat seine bevorstehende Teilnahme an der Jefferies Global Healthcare Conference 2025 angekündigt. Das Management des Unternehmens wird an einem Fireside-Chat teilnehmen, der für Donnerstag, den 5. Juni um 12:50 Uhr ET in New York City geplant ist. Investoren und Interessierte können sowohl die Live-Präsentation als auch die Wiederholung über den Bereich Veranstaltungen auf der Investor-Relations-Website von Lexicon unter https://investors.lexpharma.com/ verfolgen.
- None.
- None.
THE WOODLANDS, Texas, May 29, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference, taking place in New York City on Thursday, June 5 at 12:50 p.m. ET.
The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.
About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through the Genome5000™ program, Lexicon’s unique genomics target discovery platform, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon has advanced multiple medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in heart failure, neuropathic pain, obesity, cardiology, diabetes and other indications. For additional information, please visit www.lexpharma.com.
For Investor and Media Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com
